Comerica Bank’s Corvus Pharmaceuticals CRVS Stock Holding History

Comerica Bank’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-365	Closed	-$1.46K	–	3730
2025 Q2	$1.46K	Buy	+365	New	+$1.33K	﹤0.01%	3546

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Comerica Bank's CRVS Position: Q3 2025 in Review

Comerica Bank sold out of Corvus Pharmaceuticals (CRVS) in Q3 2025, closing a stake of 365 shares — an estimated $1.46K sold.

Comerica Bank first reported a position in CRVS in Q2 2025 and held it in 1 quarter. The position peaked at $1.46K in Q2 2025. 102 funds tracked by Wall St. Rank hold CRVS as of Q3 2025.

Comerica Bank reported no remaining Corvus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Comerica Bank sold 365 Corvus Pharmaceuticals shares in Q3 2025, an estimated $1.46K.
Comerica Bank first reported a position in Corvus Pharmaceuticals in Q2 2025 and held it in 1 quarter.
Comerica Bank's Corvus Pharmaceuticals position peaked at $1.46K in Q2 2025.
102 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2025.

Based on Comerica Bank's 13F filing for Q3 2025, filed 14 Nov 2025.